Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
An update from IRLAB Therapeutics AB Class A ( ($SE:IRLAB.A) ) is now available.
IRLAB Therapeutics AB has announced the appointment of its nomination committee for the 2026 annual general meeting. The committee includes representatives from the company’s largest shareholders, collectively holding about 36% of shares and votes, and will present proposals for the AGM scheduled for May 20, 2026. This move is part of IRLAB’s ongoing corporate governance efforts, reflecting its commitment to shareholder engagement and strategic planning.
The most recent analyst rating on ($SE:IRLAB.A) stock is a Sell with a SEK2.50 price target. To see the full list of analyst forecasts on IRLAB Therapeutics AB Class A stock, see the SE:IRLAB.A Stock Forecast page.
More about IRLAB Therapeutics AB Class A
IRLAB Therapeutics AB is a Swedish company focused on discovering and developing innovative treatments for Parkinson’s disease. Originating from Nobel Laureate Prof Arvid Carlsson’s research, the company is advancing a portfolio of transformative treatments, including Mesdopetam, Pirepemat, and IRL757, through various clinical phases. IRLAB is listed on Nasdaq Stockholm.
Average Trading Volume: 209,551
Technical Sentiment Signal: Sell
Current Market Cap: SEK192M
For detailed information about IRLAB.A stock, go to TipRanks’ Stock Analysis page.